Iambic Therapeutics, Inc. (IAM) vs Nuvectis Pharma, Inc. (NVCT)

Iambic Therapeutics, Inc. IAM 10.20 −12.37%
Nuvectis Pharma, Inc. NVCT 20.81 +17.17%

Iambic Therapeutics, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Iambic Therapeutics, Inc. and Nuvectis Pharma, Inc. are of similar size ($579.8M and $551.7M).

Metric	IAM	NVCT	Biotechnology median
P/E	—	n/m	10.60
P/S	—	n/m	9.40
P/B	—	4.84	2.13
Price to free cash flow	—	n/m	25.18
EV/EBITDA	—	n/m	0.66
EV/Sales	—	n/m	9.02
Earnings yield	—	(9.08%)	(32.88%)
Free cash flow yield	—	(6.57%)	(23.13%)

Metric	IAM	NVCT	Biotechnology median
Gross margin	—	—	68.51%
Operating margin	—	0.00%	0.00%
Net margin	—	0.00%	0.00%
Free cash flow margin	—	0.00%	0.00%
Return on equity	—	(66.98%)	(51.96%)
Return on assets	—	(57.20%)	(46.06%)
Return on invested capital	—	0.00%	0.00%

Metric	IAM	NVCT	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	—	(18.92%)	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	IAM	NVCT	Biotechnology median
Debt to equity	—	0.00	0.00
Current ratio	—	9.92	4.97
Net debt to EBITDA	—	1.15	1.01

Metric	IAM	NVCT	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	IAM	NVCT	Biotechnology median
Market cap	551.74m	579.76m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack